Is clozapine safe in the elderly?

Australian and New Zealand Journal of Psychiatry

Volumn 31, Issue 3, 1997, Pages 411-417

  Herst, Laurence ^a   Powell, Geoff ^a  

^a ROYAL HOBART HOSPITAL   (Australia)

Author keywords

Agranulocytosis; Clozapine; Psychogeriatric

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

AGED; AGRANULOCYTOSIS; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONFUSION; CONSTIPATION; DELIRIUM; DRUG EFFICACY; FEMALE; GERONTOPSYCHIATRY; HUMAN; LEUKOPENIA; MALE; MEDICAL LITERATURE; NAUSEA; ORTHOSTATIC HYPOTENSION; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; TACHYCARDIA; VERTIGO; VOMITING;

EID: 0030792493     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.3109/00048679709073852     Document Type: Article

References (33)

1. Kane JM Clinical efficacy of clozapine in treatment-refractory schizophrenia. An overview British Journal of Psychiatry 1992, 17:41-45.
2. Meltzer HY Treatment of the neuroleptic non responsive schizophrenic patient. Schizophrema Bulletin 1992; 18:515-542.
3. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. Journal of Clinical Psychiatry 1994; 9 161-165
4. Krupp P, Barnes P. Clozapine-associated agranulocytosis: risk and aetiology. British Journal of Psychiatry 1992; 160:38-40.
5. Alvir JMJ, Jeffrey PH, Lieberman A, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis: incidence and risk factor in the United States. New England Journal of Medicine 1993; 329.162-167.
6. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis Psychiatry Quarterly 1993,63.51-70
7. Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio V. Agranulocytosis in patients treated with clozapine. Study of the Finnish epidemic. Acta Psychiatrics Scandinavica 1977; 56.241-248.
8. Lieberman JA, Yunis J, Egea E, Canosa RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQW3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry 1990; 47 945-948
9. Yunis J, Corzo D, Salazar M, Lieberman JA, Howard A, Yunis EJ. HLA Associations in clozapine-induced agranulocytosis. Blood 1995; 86: 1177-1183.
10. Nandel A, Gross M Agranulocytosis and phenothiazines. Diseases of the Nervous System 1968. 29 32-36
11. Pisciotta AV. Agranulocytosis-induced by phenothiazine derivatives. Journal of the American Medical Association 1969,208:1862-1868.
12. Heimpel H. Drug-induced agranulocytosis Medical Toxicology 1988; 3:449-462.
13. Gersen SL. G-CSF and the management of clozapineinduced agranulocytosis. Journal of Clinical Psychiatry 1994; 9:139-142.
14. Mendelowitz AJ, Gerson SL, Alvir JMJ, Liberman JA. Clozapine-induced agranulocytosis: risk factors, monitoring and management. CNS Drugs 1995, 4:412-421.
15. Matz R, Rick W, Oh D, Thompson H, Gershon S. Clozapine: a potential antipsychotic agent without extrapyramidal manifestations. Current Therapeutic Research 1974; 16:687-695.
16. Kaplan HI, Sadock BJ Clozapine: antipsychotic. In: Psychiatric drug treatment. Baltimore: Williams and Wilkins, 1993:91-97.
17. Kahn N, Freeman A, Juncos JL, Manning D, Watts RL. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991; 41:1699-1700.
18. Szymanski S, Jody D, Leipzig R, Maziar S, Lieberman J. Anticholinergic delirium caused by retreatment with clozapine. American Journal of Psychiatry 1991; 148:1752.
19. Pitner JK, Mintzer JE, Pennypacker LC, Jackson CW. Efficacy and adverse effects of clozapine in four elderly psychotic patients. Journal of Clinical Psychiatry 1995; 56:180-185.
20. Having C, Merse V, Huenpel C et al Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacy 1989; 99 538-540
21. Certorrino F, Baldessarini RJ, Flood JG et al. Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites. American Journal of Psychiatry 1995; 152:610-612.
22. Oberholzer AF, Herdriksen C, Monsch AV et al. Safety and effectiveness of low dose clozapine in psychogeriatric patients: preliminary study. International Psychogeriatrics 1992;4:187-195
23. Chengappa KNR, Baker RW, Kreinbrook SB, Adair D. Clozapine use in female geriatric patients with psychoses, Journal of Geriatric Psychiatry and Neurology 1995; 8:12-15.
24. Salzman C, Vaccaro B, Lieff J, Weiner A. Clozapine in older patients with psychosis and behavioural disruption American Journal of Geriatric Psychiatry 1995; 3:26-33.
25. Frankenburg FR, Kalunian D. Clozapine in the elderly Journal of Geriatric Psychiatry and Neurology 1994; 7:129-132
26. Wolk SI, Douglas CJ. Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. Journal of Clinical Psychiatry 1992; 53.373-376.
27. Wolters EC, Hurwitz TA, Mak E et al. Clozapine in the treatment of Parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40:832-834.
28. Gowlland RW. Troubled asylum New Norfolk, Tasmania: Gowlland, 1981.
29. Mamus SW, Burton JD, Groat JD, Schulte DA, Lobell M, Zanjanhi ED. Ibuprofen-associated pure white cell aplasia. New England Journal of Medicine 1986; 314:624-625.
30. List AF, Beaird PH, Klummet T. Ranitidine-induced granulocytopenia: recurrence with cimetidine administration. Annals of Internal Medicine 1988, 108.566-567.
31. Jones JK. Hepatotoxicity associated with phenothiazines. Psychopharmacology Bulletin 1983; 19:24-27.
32. Stahl SM. Conventional neuroleptic drugs for schizophrenia and novel anti-psychotic agents. In Essential psychopharmacology. Melbourne: Cambridge University Press, 1996:263-288.
33. Carlsson A. Recent advances in the therapeutics of schizophrenia is dopamine still relevant? European Neuropsychopharmacology 1996; 6:67